References
- Stramer BM, Mori R, Martin P. The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol. [Internet]. 2007;127:1009–1017.
- Rieder F, Brenmoehl J, Leeb S, et al. Wound healing and fibrosis in intestinal disease. Gut. Internet. 2007;56:130–139.
- von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63–73.
- Creamer B, Shorter RG, Bamforth J. The turnover and shedding of epithelial cells. I. The turnover in the gastro-intestinal tract. Gut. 1961;2:110–118.
- Park J, Kotani T, Konno T, et al. Promotion of intestinal epithelial cell turnover by commensal bacteria: role of short-chain fatty acids. PLoS One. [Internet]. 2016;11:e0156334.
- Bonnans C, Chou J, Werb Z, Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. [Internet]. 2014 cited 2014 Nov 21;15: 786–801.
- Shimshoni E, Yablecovitch D, Baram L, et al. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut. 2015;64:367–372.
- Petrey AC, de la Motte CA. The extracellular matrix in IBD. Curr Opin Gastroenterol. Internet. 2017;33:234–238. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28562487%0Ahttp://Insights.ovid.com/crossref?an=00001574-201707000-00005
- Rath T, Roderfeld M, Graf J, et al. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis. Internet. 2006;12:1025–1035. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17075343.
- Schuppan D, Freitag T. Fistulising Crohn’s disease: mMPs gone awry. Gut. 2004;53:620–622.
- Koelink PJ, Overbeek SA, Braber S, et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut. [Internet]. 2014 cited 2015 Mar 19;63:578–587. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3963538&tool=pmcentrez&rendertype=abstract
- Mäkitalo L, Rintamäki H, Tervahartiala T, et al. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. Internet. 2012 cited 2015 Feb 12;47:785–794. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22519363.
- Mortensen JH, Godskesen LE, Jensen MD, et al. Fragments of citrullinated and MMP-degraded Vimentin and MMP-degraded type III collagen are novel serological biomarkers to differentiate Crohn’s disease from ulcerative colitis. J Crohn’s Colitis. [Internet]. 2015;jjv123. DOI:10.1093/ecco-jcc/jjv123.
- van Haaften WT, Mortensen JH, Karsdal MA, et al. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease. Aliment Pharmacol Ther. Internet. 2017. DOI:10.1111/apt.14092.
- Mortensen JH, Manon-Jensen T, Jensen MD, et al. Ulcerative colitis, Crohn’s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn’s disease. PLoS One. 2017;12:1–16.
- Latella G, Di Gregorio J, Flati V, et al. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand. J. Gastroenterol. 2014;50:53–65.
- OʼShea NR, Smith AM. Matrix metalloproteases role in bowel inflammation and inflammatory bowel disease: an up to date review. Inflamm Bowel Dis. Internet. 2014 cited 2014 Sep 26;1–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25222664
- Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease. Gut. 2004;53:701–709.
- Bennike TB, Carlsen TG, Ellingsen T, et al. Neutrophil extracellular traps in ulcerative colitis: a proteome analysis of intestinal biopsies. Inflamm Bowel Dis. Internet. 2015;1. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00054725-900000000-99155
- Bond JS, Matters GL, Banerjee S, et al. Meprin metalloprotease expression and regulation in kidney, intestine, urinary tract infections and cancer. FEBS Lett. 2005;579:3317–3322.
- Latella G, Rogler G, Bamias G, et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. J Crohns Colitis. [Internet]. 2014 cited 2014 Jul 13. Available from: http://www.sciencedirect.com/science/article/pii/S1873994614001202
- Latella G, Sferra R, Speca S, et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. Internet. 2013;17:1283–1304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23740440.
- Gelse K, Pöschl E, Collagens AT. - Structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55:1531–1546.
- Shimshoni E, Yablecovitch D, Baram L, et al. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut. 2014;64:367–372.
- Petrey AC. De La Motte CA. The extracellular matrix in IBD: A dynamic mediator of inflammation. Curr Opin Gastroenterol. 2017;33:234–238.
- Karsdal MA, Nielsen MJ, Sand JM, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. [Internet]. 2013;11:70–92. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3593693&tool=pmcentrez&rendertype=abstract.
- Karsdal MA, Nielsen SH, Leeming DJ, et al. The good and the bad collagens of fibrosis – their role in signaling and organ function. Adv Drug Deliv Rev. 2017;121.
- Karsdal MA, Leeming DJ, Heniksen K, et al. Biochemistry of collagens, laminins and elastin: structure, function and biomarkers [Internet]. 2nd ed. MA K, editor. Book. 125 London Wall, London EC2Y 5AS, United Kingdom; 525 B Street, Suite 1650, San Diego, CA 92101, United States; 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States; The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom: Elsevier Inc.; 2019. Available from: https://www.elsevier.com/books-and-journals.
- Villone D, Fritsch A, Koch M, et al. Supramolecular interactions in the dermo-epidermal junction zone: anchoring fibril-collagen VII tightly binds to banded collagen fibrils. J Biol Chem. [Internet]. 2008 cited 2015 Mar 16;283:24506–24513. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3259843&tool=pmcentrez&rendertype=abstract
- Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003;200:423–428.
- Yurchenco P. Molecular architecture of basement-membranes. Faseb J. 1990;4.
- Reinboth B, Hanssen E, Cleary EG, et al. Molecular interactions of biglycan and decorin with elastic fiber components: biglycan forms a ternary complex with tropoelastin and microfibril-associated glycoprotein 1. J Biol Chem. [Internet]. 2002 cited 2014 Sep 15;277:3950–3957. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11723132
- Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123:4195–4200.
- Koch M, Veit G, Stricker S, et al. Expression of type XXIII collagen mRNA and protein. J Biol Chem. 2006;281:21546–21557.
- Henry-Stanley MJ, Hess DJ, Erlandsen SL, et al. Ability of the heparan sulfate proteoglycan syndecan-1 to participate in bacterial translocation across the intestinal epithelial barrier. Shock. 2005;24:571–576.
- Wang Z, Li R, Tan J, et al. Syndecan-1 acts in synergy with tight junction through Stat3 signaling to maintain intestinal mucosal barrier and prevent bacterial translocation. Inflamm Bowel Dis. 2015;21:1894–1907.
- Hussey GS, Keane TJ, Badylak SF. The extracellular matrix of the gastrointestinal tract: a regenerative medicine platform. Nat Rev Gastroenterol Hepatol. 2017.
- Leinonen A, Mariyama M, Mochizuki T, et al. Complete primary structure of the human type IV collagen alpha4(IV) chain. Comparison with structure and expression of the other alpha(IV) chains. J Biol Chem. 1994;269:26172–26177.
- Oka Y, Naito I, Manabe K, et al. Distribution of collagen type IV 1-6 chains in human normal colorectum and colorectal cancer demonstrated by immunofluorescence staining using chain-specific epitope-defined monoclonal antibodies. J Gastroenterol Hepatol. 2002;17:980–986.
- Simon-Assmann P, Bouziges F, Arnold C, et al. Epithelial-mesenchymal interactions in the production of basement membrane components in the gut. Development. 1988;102:339–347.
- Kirkland SC, Henderson K. Collagen IV synthesis is restricted to the enteroendocrine pathway during multilineage differentiation of human colorectal epithelial stem cells. J Cell Sci. 2001;114:2055–2064.
- J-F G, Gagné D, Benoit YD, et al. Collagen VI is a basement membrane component that regulates epithelial cell-fibronectin interactions. Matrix Biol. [Internet]. 2011 cited 2014 Jun 2;30:195–206. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21406227
- Kuo HJ, Maslen CL, Keene DR, et al. Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J Biol Chem. 1997;272:26522–26529.
- Tillet E, Wiedemann H, Golbik R, et al. Recombinant expression and structural and binding properties of alpha 1(VI) and alpha 2(VI) chains of human collagen type VI. Eur J Biochem. 1994;221:177–185.
- Bidanset DJ, Guidry C, Rosenberg LC, et al. Binding of the proteoglycan decorin to collagen type VI. J Biol Chem. 1992;267:5250–5256.
- Wiberg C, Hedbom E, Khairullina A, et al. Biglycan and decorin bind close to the n-terminal region of the collagen VI triple helix. J Biol Chem. Internet. 2001 cited 2014 Sep 15;276:18947–18952. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/11259413
- Kittelberger R, Davis PF, Flynn DW, et al. Distribution of type VIII collagen in tissues: an immunohistochemical study. Connect Tissue Res. 1990;24:303–318.
- Weitkamp B, Cullen P, Plenz G, et al. Human macrophages synthesize type VIII collagen in vitro and in the atherosclerotic plaque. FASEB J Off Publ Fed Am Soc Exp Biol. 1999;13:1445–1457.
- Ruger B, Dunbar PR, Hasan Q, et al. Human mast cells produce type VIII collagen in vivo. Int J Exp Pathol. 1994;75:397–404.
- Adiguzel E, Hou G, Sabatini PJB, et al. Type VIII collagen signals via β1 integrin and RhoA to regulate MMP-2 expression and smooth muscle cell migration. Matrix Biol. [Internet]. 2013 cited 2018 Nov 7;32:332–341. Available from: https://www.sciencedirect.com/science/article/pii/S0945053X13000486?via%3Dihub
- Teller IC, Beaulieu JF. Interactions between laminin and epithelial cells in intestinal health and disease. Expert Rev Mol Med. 2001;3:1–18.
- Turck N, Gross I, Gendry P, et al. Laminin isoforms: biological roles and effects on the intracellular distribution of nuclear proteins in intestinal epithelial cells. Exp Cell Res. 2005;303:494–503.
- Iozzo R. Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol. 2005;6:646–656.
- Manon-Jensen T, Itoh Y, Couchman JR. Proteoglycans in health and disease: the multiple roles of syndecan shedding. Febs J. 2010;277:3876–3889.
- Simon-Assmann P, Bouziges F, Vigny M, et al. Origin and deposition of basement membrane heparan sulfate proteoglycan in the developing intestine. J Cell Biol. 1989;109:1837–1848.
- Gubbiotti MA, Neill T, Iozzo RV. A current view of perlecan in physiology and pathology: A mosaic of functions. Matrix Biol. 2017;57–58:285–298.
- Pousa ID, Maté J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest. 2008;38:73–81.
- Hohenester E, Yurchenco PD, Hohenester E, et al. Laminins in basement membrane assembly. Cell Adhes Migr. 2013;7:56–63.
- Simon-Assmann P, Kedinger M, De Arcangelis A, et al. Extracellular matrix components in intestinal development. Experientia. 1995;51:883–900.
- Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm. Bowel Dis. [Internet]. 2001;7:16–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11233656
- Hulmes DJS. Collagen diversity, synthesis and assembly. In: Fratzl P, editor. Collagen Struct. Mech. [Internet]. Boston, MA: Springer US; 2008. p. 15–47. DOI:10.1007/978-0-387-73906-9_2.
- Yamauchi M, Shiiba M. Lysine hydroxylation and cross-linking of collagen. In: Kannicht C, editor. Post-translational Modif. proteins tools funct. proteomics [Internet]. Totowa, NJ: Humana Press; 2008. p. 95–108. DOI:10.1007/978-1-60327-084-7_7.
- Bella J, Hulmes DJS. Fibrillar Collagens. In: Parry DAD, Squire JM, editors. Fibrous Proteins Struct. Mech. [Internet]. Cham: Springer International Publishing; 2017. p. 457–490. DOI:10.1007/978-3-319-49674-0_14.
- Bourhis J-M, Vadon-Le Goff S, Afrache H, et al. Procollagen C-proteinase enhancer grasps the stalk of the C-propeptide trimer to boost collagen precursor maturation. Proc Natl Acad Sci. 2013;110:6394–6399.
- Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet. [Internet]. 2004;20:33–43. Available from.
- Kivirikko KI, Myllyla R. Posttranslational enzymes in the biosynthesis of collagen: intracellular enzymes. Methods Enzymol. 1982;82(Pt A):245–304.
- Liu X, Wu H, Byrne M, et al. Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development (gene targeting͞Ehlers–danlos syndrome type IV͞aortic rupture). Dev Biol. 1997;94:1852–1856.
- Graham MF, Diegelmann RF, Elson CO, et al. Collagen content and types in the intestinal strictures of Crohn’s disease. Gastroenterology. 1988;94:257–265.
- Birk DE. Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril assembly. Micron. Internet. 2001;32:223–237. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11006503
- Mikula M, Rubel T, Karczmarski J, et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics. 2011;11:215–224.
- Ratzinger S, Eble JA, Pasoldt A, et al. Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal tract. Matrix Biol. 2010;29:177–193.
- Myers JC, Li D, Bageris A, et al. Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. Am J Pathol. 1997;151:1729–1740.
- Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol. 2005;53:430–442.
- Wise SG, Weiss AS. Tropoelastin. Int J Biochem Cell Biol. [Internet]. 2009;41:494–497. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1357272508001453
- Lowery MC, Morris CA, Ewart A, et al. Strong correlation of elastin deletions, detected by FISH, with Williams syndrome: evaluation of 235 patients. Am J Hum Genet. [Internet]. 1995;57:49–53. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1801249&tool=pmcentrez&rendertype=abstract.
- Deshpande AV, Oliver M, Yin M, et al. Severe colonic diverticulitis in an adolescent with Williams syndrome. J Paediatr Child Health. 2005;41:687–688.
- Schönherr E, Lugering N, Stoll R, et al. Differences in Decorin and Biglycan Expression in Patients with Gastric Ulcer Healing. Scand J Gastroenterol. [Internet]. 1997;32:785–790.
- Imai K, Hiramatsu A, Fukushima D, et al. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 1997;322(Pt 3):809–814.
- Karsdal MA, Nielsen MJ, Sand JM, et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol. 2013;11:70–92.
- Nastase MV, Young MF, Schaefer L. Biglycan: A Multivalent Proteoglycan Providing Structure and Signals. J Histochem Cytochem. [Internet]. 2012;60:963–975.
- Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. [Internet]. 2005;115:2223–2233. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1174916&tool=pmcentrez&rendertype=abstract.
- Kruse M-N, Becker C, Lottaz D, et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004;378:383–389.
- Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094–1108.
- Karlinger K, Györke T, Makö E, et al. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol. Internet. 2000;35:154–167. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19385381.
- Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17:116–121.
- Hundorfean G, Neurath MF, Sitaru C. Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med. Internet. 2010 cited 2014 Jun 12;14:2393–2403. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19878366
- Selmi C. Autoimmunity in 2012. Clin Rev Allergy Immunol. [Internet]. 2013 cited 2014 Jun 12;45:290–301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23975606
- Monteleone G, Caruso R, Fina D, et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut. 2006;55:1774–1780.
- Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. [Internet]. 2014;14:329–342.
- Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. [Internet]. 2017;38:127–142.
- Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. [ Internet]. 2014;7:6–19.
- Ishiguro N, Ito T, Miyazaki K, et al. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J Rheumatol. 1999;26:34–40.
- Rose BJ, Kooyman DL. A tale of two joints : the role of matrix metalloproteases in cartilage biology. Disease Markers. 2016.
- Paoliello-Paschoalato AB, Marchi LF, De AMF, et al. FC-gamma and complement receptors and complement proteins in neutrophil activation in rheumatoid arthritis: contribution to pathogenesis and progression and modulation by natural products. evidence-based complement. Altern Med. 2015;2015.
- Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41:271–290.
- Pasternak B, Aspenberg P. Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop. 2009;80:693–703.
- Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814–822.
- Gao Q, Meijer MJW, Kubben FJGM, et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig. Liver Dis. 2005;37:584–592.
- Garg P, Vijay-Kumar M, Wang L, et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G175–84.
- Mäkitalo L, Kolho K-L, Karikoski R, et al. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol. 2010;45:862–871.
- Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. Internet. 2010;10:712–723.
- Fontani F, Domazetovic V, Marcucci T, et al. MMPs, ADAMs and their natural inhibitors in inflammatory bowel disease: involvement of oxidative stress. J Clin Gastroenterol Treat. 2017;3:1–12.
- Jakubowska K, Pryczynicz A, Iwanowicz P, et al. Expressions of matrix metalloproteinases (MMP-2, MMP-7, and MMP-9) and their inhibitors (TIMP-1, TIMP-2) in inflammatory bowel diseases. Gastroenterol Res Pract. 2016;2016.
- Vrhovski B, Weiss AS. Biochemistry of tropoelastin. Eur J Biochem. 1998;258:1–18.
- Herman B, Bibert S, Concord E, et al. Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem. 2003;278:14002–14012.
- Levine AP, Segal AW. What Is wrong with granulocytes in inflammatory bowel diseases. Dig Dis. 2013;31:321–327.
- Keiffer TR, Bond J. IL-6 is a newly-discovered substrate for meprin metalloproteinases. Faseb J. Internet. 2010;24:683.5. Available from: http://www.fasebj.org/content/24/1_Supplement/683.5.abstract
- Coskun M. Intestinal epithelium in inflammatory bowel disease. Front Med. 2014;1.
- Spenlé C, Lefebvre O, Lacroute J, et al. The laminin response in inflammatory bowel disease: protection or malignancy? PLoS One. 2014;9:1–13.
- Bouatrouss Y, Herring-gillam FE, Gosselin J, et al. Altered expression of laminins in Crohn’s disease small intestinal mucosa. Am J Pathol. 2000;156:45–50.
- Koutroubakis IE, Petinaki E, Dimoulios P, et al. Serum laminin and collagen IV in inflammatory bowel disease. J Clin Pathol. 2003;56:817–820.
- Zhao H, Xi H, Wei BO, et al. Expression of decorin in intestinal tissues of mice with inflammatory bowel disease and its correlation with autophagy. Experimental and Therapeutic Medicine. 2016. p. 3885–3892.
- Yablecovitch D, Stein A, Shabat-Simon M, et al. Soluble syndecan-1 levels are elevated in patients with inflammatory bowel disease. Dig Dis Sci. 2015;60:2419–2426.
- Çekiç C, Kırcı A, Vatansever S, et al. Serum syndecan-1 levels and its relationship to disease activity in patients with Crohn’s Disease. Gastroenterol Res Pract. 2015;2015:850351.
- Floer M, Götte M, Wild MK, et al. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol. 2010;176:146–157.
- Wang X, Chen Y, Song Y, et al. Activated Syndecan-1 shedding contributes to mice colitis induced by dextran sulfate sodium. Dig Dis Sci. 2011;56:1047–1056.
- Podolsky DK, Babyatsky MW, DeBeaumont M, et al. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Am J Physiol. 1999;277:G495–9.
- Arihiro S, Ohtani H, Hiwatashi N, et al. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology. [Internet]. 2001;39:50–59. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11454044.
- Kucharzik T, Maaser C, Lügering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. Internet. 2006;12:1068–1083. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/17075348.
- Gelbmann CM, Mestermann S, Gross V, et al. Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut. [Internet]. 1999;45:210–217. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1727598&tool=pmcentrez&rendertype=abstract.
- Hamilton MJ. The multifaceted mast cell in inflammatory bowel disease. Inflamm Bowel Dis. [Internet]. 2014;20:2364–2378. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4749027&tool=pmcentrez&rendertype=abstract
- Wu L, Feng B-S, He S-H, et al. Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: the role of TLR2 and NOD2. Immunol Cell Biol. 2007;85:538–545.
- Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45:571–583.
- Geboes K. Histopathology of Crohn ’ s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;18:255–276.
- Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol. Internet. 2007 cited 2014 Jun 12;115:1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17137666
- Brown C, Gibson PR, Hart A, et al. Long-term outcomes of colectomy surgery among patients with ulcerative colitis. Springerplus. 2015;4:573.
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.
- Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
- Matthes H. Celluar localization of procollagen gene transcripts in inflammatory bowel disease. Gastroenterology. 1992;102:431–442.
- Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis. 2017;11:649–670.
- Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management on behalf of ECCO. J Crohn’s Colitis. [Internet]. 2016;1–23. Available from: http://ecco-jcc.oxfordjournals.org/
- Iacucci M, Ghosh S. Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol. 2011;4:129–143.
- Göke M, Zuk A, Podolsky DK. Regulation and function of extracellular matrix intestinal epithelial restitution in vitro. Am J Physiol. 1996;271:G729–40.
- Tuomisto A, Sund M, Tahkola J, et al. A mutant collagen XIII alters intestinal expression of immune response genes and predisposes transgenic mice to develop B-cell lymphomas. Cancer Res. 2008;68:10324–10332.
- Moilanen JM, Kokkonen N, Löffek S, et al. Collagen XVII expression correlates with the invasion and metastasis of colorectal cancer. Hum Pathol. [Internet]. 2015;46:434–442.
- Lindholm M, Manon-Jensen T, Madsen GI, et al. Extracellular matrix fragments of the basement membrane and the interstitial matrix are serological markers of intestinal tissue remodeling and disease activity in dextran sulfate sodium colitis. Dig Dis Sci. [Internet]. 2019. DOI:10.1007/s10620-019-05676-6.
- Stronati L, Palone F, Negroni A, et al. Dipotassium glycyrrhizate improves intestinal mucosal healing by modulating extracellular matrix remodeling genes and restoring epithelial barrier functions. Front Immunol. 2019;10:1–14.
- Schmehl K, Florian S, Jacobasch G, et al. Deficiency of epithelial basement membrane laminin in ulcerative colitis affected human colonic mucosa. Int J Colorectal Dis. 2000;15:39–48.
- Kirov S, Sasson A, Zhang C, et al. Degradation of the extracellular matrix is part of the pathology of ulcerative colitis. 2018;1–26.
- Karsdal MA, Bay-Jensen AC, Leeming DJ, et al. Quantification of “end products” of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways – implications for modern clinical chemistry. Biomarkers. [Internet]. 2013;18:375–378. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23721060.
- Goffin L, Fagagnini S, Vicari A, et al. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis. Inflamm Bowel Dis. 2016;22:2041–2057.
- Efsen E, Saermark T, Hansen A, et al. Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn’s disease fistulas. Basic Clin Pharmacol Toxicol. 2011;109:208–216.
- Oberhuber G, Stangl PC, Vogelsang H, et al. Significant association of strictures and internal fistula formation in Crohn’s disease. Virchows Arch. 2000;437:293–297.
- Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration. Nature. 2016;529:307–315.
- Burke JP, Mulsow JJ, O’Keane C, et al. Fibrogenesis in Crohn’s disease. Am J Gastroenterol. 2007;102:439–448.
- Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. Hepatology. 2019;69:1075–1086.
- Sand JMB, Knox AJ, Lange P, et al. Accelerated extracellular matrix turnover during exacerbations of COPD. Respir Res. 2015;16.
- Rieder F, De BJR, Tung B, et al. Results of the 4th Scientific Workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. 2014;1166–1178. Available from: https://c117a3hmi8d9eqb5ef.amc-literatuur.amc.nl/S1873994614001214/1-s2.0-S1873994614001214-main.pdf?_tid=73d48e76-78c1-11e5-887b-00000aab0f6b&acdnat=1445520977_3bfdf6da60be0f57970f045a799d2a76.
- Rieder F, Fiocchi C. Intestinal fibrosis in IBD - a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228–235.
- Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1–16.
- Kendall RT, Feghali-Bostwick CA. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:1–13.
- Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2011;300:G677–83.
- Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. [Internet]. 2011 cited 2014 May 29;179:2660–2673. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3204019&tool=pmcentrez&rendertype=abstract
- Speca S, Giusti I, Rieder F, et al. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol. 2012;18:3635–3661.
- Wynn TA, Ph D, Barron L. Macrophages: master Regulators of Inflammation and Fibrosis. Liver. 2011;3:245–257.
- Bailey JR, Bland PW, Tarlton JF, et al. IL-13 promotes collagen accumulation in Crohn’s disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells?. PLoS One. [Internet]. 2012 cited 2015 May 18;7:e52332. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3534115&tool=pmcentrez&rendertype=abstract
- Rieder F, Fiocchi C. Mechanisms of tissue remodeling in inflammatory bowel disease. Dig Dis. 2013;31:186–193.
- Ippolito C, Colucci R, Segnani C, et al. Fibrotic and vascular remodelling of colonic wall in patients with active ulcerative colitis. J Crohns Colitis. 2016;10:1194–1204.
- Higgins PDR. Measurement of fibrosis in Crohn’s disease strictures with imaging and blood biomarkers to inform clinical decisions. Dig Dis. 2017;35:32–37.
- Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17:1415–1422.
- Karsdal MA, Henriksen K, Leeming DJ, et al. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers–are they the cause or the consequence of the disease? Clin Biochem. [Internet]. 2010 cited 2014 May 28;43:793–804. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20381482